Grace Therapeutics (GRCE) Director Davis A. Brian Receives Award

What Happened Davis A. Brian, a director of Grace Therapeutics (GRCE), was reported as receiving a derivative award (Form 4 code A) on 2026-09-17. The filing lists the number of derivative securities as "N/A" and a reported price of $0.00; no dollar value or post-transaction share count is provided. This is an award/grant (compensation) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-17 (reported on Form 4 filed 2026-09-21).
• Reported consideration: $0.00; number of derivative securities: listed as N/A.
• Shares owned after transaction: not reported in the filing.
• Footnote: 50% of the award vests on the grant date; the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to continuous service.
• Filing timing: Form 4 was posted four days after the transaction date (outside the typical 2 business-day filing window), so the filing appears late.

Context This was a derivative award (the filing does not specify whether it is stock options, RSUs, or another form of derivative). Because the award vests over time, it does not represent immediate market buying or selling. Awards are commonly part of director compensation; without a disclosed quantity or value, the filing does not allow assessment of the economic size or immediate impact on insider ownership.